Ted Okerson

TL;DR: The aim of this study was to evaluate the efficacy and tolerability of exenatide monotherapy in patients with type 2 diabetes naive to antidiabetic agents and whose disease was inadequately controlled with diet and exercise alone.

TL;DR: Although this study was limited by a 2-week duration of exposure, data demonstrate that, exenatide had a greater effect than sitagliptin to lower postprandial glucose and a more potent effect to increase insulin secretion and reduce insulin secretion in T2D patients.

TL;DR: The results support the need for a prospective, randomized, controlled study of BP changes during exenatide treatment in patients with hypertension and type 2 diabetes.

TL;DR: Both incretin mimetics and DPP-4 inhibitors address both the underlying pathophysiology and overcome several of the limitations of established therapies by providing improvements in glycemia, and control of body weight with minimal risk of hypoglycemia.

TL;DR: Exenatide represents a unique option for adjunctive therapy for patients with type 2 diabetes not achieving adequate glycemic control on oral antidiabetic agents, especially in patients for whom weight gain would be an additional contraindication.